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Performance (AIP) tool was developed by combining Microsoft
Visual Basic 6.0 with a series of SQL statements that transform
pharmacy databases into a standardized format. Once stan-
dardized, a second series of SQL statements were applied to
allow tracking of prescription activity levels compared to
expected activity levels over sequentially overlapping periods of
time. RESULTS: AIP detects trends in medication adherence rel-
atively early after the initiation of adherence improvement activ-
ities. This represents a signiﬁcant improvement over traditional
methods for studying the impact of patient interventions on med-
ication adherence and provides opportunities for early modiﬁ-
cation of adherence improvement activities that do not achieve
their intended goals. CONCLUSIONS: AIP allows targeting of
speciﬁc patients for adherence interventions based on persis-
tence. Through use of dynamic ﬁlters, AIP can also identify
health care providers and institutions where adherence improve-
ment initiatives are most needed. Additionally, user-deﬁned ther-
apeutic groupings and intent to treat categorization allows AIP
to generate accurate medication adherence information when
patients are initiated on one medication in a therapeutic class but
ultimately maintained on another medication within a deﬁned
therapeutic class. The Adherence Index of Performance provides
a unique means for monitoring the impact of medication adher-
ence improvement initiatives through analysis of pharmacy
claims databases. AIP converts claims databases into a stan-
dardized format upon which a series of pre-deﬁned analytical
processes can be applied. This allows tracking of prescription
activity levels for both new and continuing patients compared to
expected activity levels over sequentially overlapping periods of
time. It has been successfully used by a number of health care
providers to monitor the impact of adherence interventions on
patients’ medication-taking behaviors.
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OBJECTIVES: Estimates of ﬁxed funding budgets can only be
accurate if all pathology related insurance costs are considered.
In this work we analysed the predictive value of LOS and PT
cost on TH insurance cost as surrogates for total budget esti-
mation. These predictors may already be available prior to the
various other cost elements and act as management indicators.
METHODS: Belgian hospitals register admission data in MBDS;
the Health Authorities make annual data freely available via 
the web (https://tct.fgov.be/etct/) on insurance costs (medicines,
medical or surgical procedures, laboratory requests, others)
relating to hospital stays per All Patients Reﬁned Diagnosis
Related Groups (APRDRG) and per stay severity. Data from 
the year 2000 were analyzed in SPSSWIN12.0 using multiple
forward stepwise linear regression. For each variable the median
value was used. Data transformations were used if appropriate.
RESULTS: On APRDRG-level median TH-cost was signiﬁcantly
correlated to HS-cost (r = 0.858, p < 0.0001) and PT-cost (r =
0.708, p < 0.0001). Median TH-cost increased with stay sever-
ity (minor 1728 Euro, extreme 8984 Euro).The linear regression
model considered the inclusion of the factors LOS, PT-cost, mean
patient age and stay severity on TH-cost; the selected model had
an adjusted R2 = 0.767 and included LOS (change in R2 = 0.691),
PT-cost (change in R2 = 0.038) and minor to moderate severity
(all factors with p < 0.001).The model ﬁtted the data of >340
APRDRGs; liver transplantation, major cardio-vascular surgery,
threatened abortion and alcohol abuse may beneﬁt from speciﬁc
modeling. CONCLUSIONS: LOS and pharmaceutical treatment
cost allow explaining >70% of the variance of the total hospi-
tal-cost as measured in real life MBDS-data; these predictors may
be useful as budget management indicators for a majority of
APRDRGs before detailed ﬁnancial data become available.
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OBJECTIVE: To evaluate the opportunity of introducing new
technologies in the medical device formulary of the Azienda
Ospedaliera di Verona. As an example, kyphoplasty evaluation
is described. METHODS: In order to control the medical devices
purchasing process, at the Azienda Ospedaliera di Verona (two
hospitals, one teaching and one general, accounting for about
2000 beds) a multidisciplinary Medical Devices Formulary Com-
mittee (MDFC) was established. The tasks of the MDFC are: to
evaluate the introduction of new medical devices in the hospital
formulary; to monitor the appropriate use of medical devices
after their introduction. The committee approves the introduc-
tion into the formulary of new medical devices with innovative
features, based on documented efﬁcacy and a favourable
cost/beneﬁt ratio. For kyphoplasty, efﬁcacy data were collected
from published literature. Cost information was computed
taking into account: the cost of the device, the personnel, the
operating room, length of stay, from the hospital perspective.
RESULTS: At the time of the evaluation, published evidence
describing the efﬁcacy of kyphoplasty consisted mostly of uncon-
trolled retrospective studies. Regarding cost, the overall cost of
the procedure was calculated as follows: device €2250, medical
and nursing staff €486, health materials and operating room
€185, length of stay €2600, for a total of €5521. The DRG reim-
bursement associated with the use of kyphoplasty with no com-
plications is €4200, which does not cover the overall cost of 
the procedure. CONCLUSIONS: Despite poor clinical data and
unfavourable economic analysis, the MDFC approved the use of
kyphoplasty only for 10 selected patients per year, requiring the
physician to report the outcomes of the treated patients, in order
to re-evaluate the use in the future.
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Newly developed, already licensed, high-priced medical devices
for critically ill patients impose additional costs especially on the
hospital sector. In countries with a DRG-based reimbursement
system there are no economic incentives for hospitals to use the
new technologies as long as the additional costs are not com-
pensated. OBJECTIVES: The objective of this paper is to analyse
the structures of the German health care system which are
involved in the implementation of new high-priced medical tech-
nologies the hospital sector in the reimbursement system and 
to determine key factors of a successful implementation.
METHODS: The institutions involved in the determination of
the catalogue of reimbursed items based on the just newly intro-
duced German DRG-system are described and examined. Illus-
trated by examples the launching of newly emerging medical
devices for inpatient treatment is analysed. Investigated parame-
ters were the number and quality of studies published, the
